ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine
Hørsholm, Denmark, 18 June 2024 – ExpreS2ion Biotech Holding AB’s ("ExpreS2ion" or the "Company") (NASDAQ First North: EXPRS2) announces that its recent webinar covering the 2024 rights issue, hosted by CEO Bent Frandsen and CFO Keith Alexander, is now available for on-demand viewing. The webinar provided insights into the background and rationale for the rights issue, detailed the intended use of proceeds, outlined the structure of the offering, and explained how to participate. Additionally, CEO Bent Frandsen has recently delivered significant presentations at